Tony Realini1, Michelle Q Lai, Laurie Barber. 1. Department of Ophthalmology, West Virginia University Eye Institute, Morgantown, West Virginia 26506, USA. realinia@rcbhsc.wvu.edu
Abstract
PURPOSE: To determine whether diabetes is a potential source of abnormal test results in glaucoma screening by use of frequency-doubling perimetry. DESIGN: Observational case series. PARTICIPANTS AND CONTROLS: Twenty-five patients with diabetes and 25 nondiabetic normal controls, all without cataract or glaucoma. METHODS: Frequency-doubling perimetry using the C-20-5 screening mode was performed in 1 randomly selected eye of each participant. Abnormal test results were immediately repeated to reduce artifacts caused by test inexperience. Frequency-doubling technology (FDT) results were assigned a numerical score between 0 (normal) and 87 (no stimuli detected). MAIN OUTCOME MEASURE: Abnormal FDT test scores. RESULTS: Overall, 7 of 25 (28%) patients with diabetes and 1 of 25 (4%) normal controls had an abnormal test; the 1 normal subject with an abnormal test was subsequently determined to have an abnormal glucose tolerance test. Four of the 7 patients with diabetes with abnormal FDT tests had no evidence of diabetic retinopathy on clinical examination. Patients with diabetes had higher test scores than normal controls (8.9+/-16.9 vs. 1.0+/-4.4, P = 0.028) and had longer test times than normal controls (66.4+/-35.5 seconds vs. 48.3+/-11.2 seconds, P = 0.019). CONCLUSIONS: Frequency-doubling perimetry is abnormal in some patients with diabetes, including some patients with diabetes without clinical evidence of diabetic retinopathy. Abnormal FDT testing in diabetic eyes may not represent glaucomatous visual field loss. Diabetes may be a source of "false-positive" test results when this technology is used for glaucoma screening.
PURPOSE: To determine whether diabetes is a potential source of abnormal test results in glaucoma screening by use of frequency-doubling perimetry. DESIGN: Observational case series. PARTICIPANTS AND CONTROLS: Twenty-five patients with diabetes and 25 nondiabetic normal controls, all without cataract or glaucoma. METHODS: Frequency-doubling perimetry using the C-20-5 screening mode was performed in 1 randomly selected eye of each participant. Abnormal test results were immediately repeated to reduce artifacts caused by test inexperience. Frequency-doubling technology (FDT) results were assigned a numerical score between 0 (normal) and 87 (no stimuli detected). MAIN OUTCOME MEASURE: Abnormal FDT test scores. RESULTS: Overall, 7 of 25 (28%) patients with diabetes and 1 of 25 (4%) normal controls had an abnormal test; the 1 normal subject with an abnormal test was subsequently determined to have an abnormal glucose tolerance test. Four of the 7 patients with diabetes with abnormal FDT tests had no evidence of diabetic retinopathy on clinical examination. Patients with diabetes had higher test scores than normal controls (8.9+/-16.9 vs. 1.0+/-4.4, P = 0.028) and had longer test times than normal controls (66.4+/-35.5 seconds vs. 48.3+/-11.2 seconds, P = 0.019). CONCLUSIONS: Frequency-doubling perimetry is abnormal in some patients with diabetes, including some patients with diabetes without clinical evidence of diabetic retinopathy. Abnormal FDT testing in diabetic eyes may not represent glaucomatous visual field loss. Diabetes may be a source of "false-positive" test results when this technology is used for glaucoma screening.
Authors: G Montesano; A Gervasoni; P Ferri; D Allegrini; L Migliavacca; S De Cillà; L Rossetti Journal: Eye (Lond) Date: 2017-03-03 Impact factor: 3.775
Authors: Hille W van Dijk; Frank D Verbraak; Marilette Stehouwer; Pauline H B Kok; Mona K Garvin; Milan Sonka; J Hans DeVries; Reinier O Schlingemann; Michael D Abràmoff Journal: Vision Res Date: 2010-08-27 Impact factor: 1.886
Authors: Hille W van Dijk; Frank D Verbraak; Pauline H B Kok; Mona K Garvin; Milan Sonka; Kyungmoo Lee; J Hans Devries; Robert P J Michels; Mirjam E J van Velthoven; Reinier O Schlingemann; Michael D Abràmoff Journal: Invest Ophthalmol Vis Sci Date: 2010-02-03 Impact factor: 4.799
Authors: Elliott H Sohn; Hille W van Dijk; Chunhua Jiao; Pauline H B Kok; Woojin Jeong; Nazli Demirkaya; Allison Garmager; Ferdinand Wit; Murat Kucukevcilioglu; Mirjam E J van Velthoven; J Hans DeVries; Robert F Mullins; Markus H Kuehn; Reinier Otto Schlingemann; Milan Sonka; Frank D Verbraak; Michael David Abràmoff Journal: Proc Natl Acad Sci U S A Date: 2016-04-25 Impact factor: 11.205
Authors: Hille W van Dijk; Pauline H B Kok; Mona Garvin; Milan Sonka; J Hans Devries; Robert P J Michels; Mirjam E J van Velthoven; Reinier O Schlingemann; Frank D Verbraak; Michael D Abràmoff Journal: Invest Ophthalmol Vis Sci Date: 2009-01-17 Impact factor: 4.799